Partnering

We are actively seeking strategic partnerships and collaborations to fully leverage the therapeutic potential of our pipeline and technology platform

Our differentiated single-cell profiling capabilities can accelerate and de-risk the clinical development of novel therapeutics. Our CelliGOTM platform and unique DISTM capabilities accelerate the discovery and development of high-quality therapeutic antibodies. They enable biomarker discovery for advanced patient stratification and enhanced probability of clinical success.

We are currently working with pharma partners to discover and validate novel therapeutic targets and to identify rare functional antibodies against complex targets.

Our key partnership interests include

Pipeline

  • Partnering our advanced immunomodulatory programs
  • Identifying novel targets and immunomodulation mechanisms
  • Out-licensing opportunities

Platform

  • Advanced development of single-cell platform tailored to development needs
  • Identifying novel targets
  • Generating high quality therapeutic antibodies against complex targets (GPCR, ion channels)
  • Discovering and validating biomarkers
  • Discovering therapeutics and antibodies from patient samples
  • Profiling tumor microenvironment

Pipeline

  • Partnering our advanced immunomodulatory programs
  • Identifying novel targets and immunomodulation mechanisms
  • Out-licensing opportunities

Platform

  • Advanced development of single-cell platform tailored to development needs
  • Identifying novel targets
  • Generating high quality therapeutic antibodies against complex targets (GPCR, ion channels)
  • Discovering and validating biomarkers
  • Discovering therapeutics and antibodies from patient samples
  • Profiling tumor microenvironment
Ready for the next steps? Contact us to learn more

Partnership Highlights

HiFiBiO Therapeutics announced a clinical trial supply agreement with Novartis for HFB200603

Read more

HiFiBiO Therapeutics announced a clinical trial supply agreement with Novartis for HFB200301

Read More

FibroGen, Inc. and HiFiBiO Therapeutics, announced an extension of their partnership

Read More

HiFiBiO Therapeutics announced a publication in Science in collaboration with the Coronavirus Immunotherapy Consortium (CoVIC)

Read More

FibroGen, Inc. and HiFiBiO Therapeutics, announced a partnership covering three HiFiBiO programs.

Read More

Kite and HiFiBio Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia

Read More

Research Collaboration to Develop Technology for the Treatment of Cancer

Read More

Research Collaboration to Develop Technology for the Treatment of Cancer

Read More